Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH

Open Biology(2020)10.1098/rsob.190235Source: DataRank Database

Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH is a research paper published in Open Biology (2020). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

Linked data & code

gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (61)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Patrick T. Bruck ORCID,M. Aladdin Bhuiyan ORCID,Amelia Mitchell-Gears,Michael J. Walsh ORCID,Kevin Zhangxu ORCID

Live enrichment

PubMed:32019478 PMC:PMC7058936

National Institutes of Health

Grant: P01 AI098681

U.S. Department of Defense

Grant: CA150378

NIDDK NIH HHS

Grant: K08 DK114563

National Institutes of Health

Grant: 5P01AI098681-03

Gene Expression Core

Claudia Adams Barr Award

goldLicense: cc-by

publisherhttps://doi.org/10.1098/rsob.190235

publisherhttps://royalsocietypublishing.org/doi/pdf/10.1098/rsob.190235

publisherhttps://royalsocietypublishing.org/doi/full-xml/10.1098/rsob.190235

repositoryhttps://doaj.org/article/5a9accc26c064d4aaaa76cdb43669cc5

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7058936

Fields of Study

0301 basic medicine03 medical and health sciencesAnimalsAntigens, NeoplasmAutoantigensCD8-Positive T-LymphocytesCamelids, New WorldCancer VaccinesCell Line, TumorDrug SynergismHistocompatibility Antigens Class IIInterleukin-2MelanomaMicePeptidesRecombinant ProteinsSingle-Domain AntibodiesVaccines, SubunitXenograft Model Antitumor Assays

MeSH Terms

CD8-Positive T-LymphocytesCell Line, TumorAnimalsCamelids, New WorldMiceMelanomaPeptidesRecombinant ProteinsInterleukin-2Cancer VaccinesVaccines, SubunitAntigens, NeoplasmHistocompatibility Antigens Class IIAutoantigensXenograft Model Antitumor AssaysDrug SynergismSingle-Domain Antibodies

Keywords

CytokinesCancer vaccinesCancer ImmunologyVhhNeoantigensAlpaca NanobodiesQH301-705.5CD8-Positive T-LymphocytesAutoantigensMiceAntigens, NeoplasmCell Line, TumorAnimalsBiology (General)MelanomaResearchHistocompatibility Antigens Class IIDrug SynergismSingle-Domain AntibodiesXenograft Model Antitumor AssaysRecombinant ProteinsVaccines, SubunitInterleukin-2PeptidesCamelids, New World

Sustainable Development Goals

SDG 3: 3. Good health

Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH

FAIR Checklist

Authors (13)

Funding (5 grants)

Open Access

Topics

Annotations (Europe PMC)